Image Credit: Angel Medical Systems
In May 2023 AngelMed changed its name to Avertix. AngelMed developed the Guardian System, which is an FDA-approved implantable device designed to detect and warn patients of acute thrombotic coronary occlusion.
BIOS Acquisition Corporation, a special purpose acquisition company, then announced that it had entered into a definitive merger agreement with Avertix so it would become a publicly traded company on Nasdaq. The Transaction is expected to close in the second half of 2023. According to the announcement, the combined company, which will be named Avertix Medical, Inc., will have an enterprise value of approximately $195 million.
Dr. Fischell received his BSME degree from Duke University and MS and Sc.D. degrees from the University of Maryland. Dr. Fischell was employed at the Johns Hopkins University where he was the Chief Engineer of the Space Department and worked on more than 50 spacecraft. His interests at Johns Hopkins then turned to the invention of new medical devices such as pacemakers and implantable heart defibrillators. Starting in 1969, Dr. Fischell began the formation of 14 private companies that licensed his patents on medical devices. These companies include Pacesetter Systems, Inc. (now called St. Jude Medical), IsoStent, Inc., NeuroPace, Inc., Neuralieve, Inc., Angel Medical Systems, Inc, and Svelte Medical Systems, Inc. Dr. Fischell is a prolific inventor with over 200 issued U.S. and foreign patents, many of which have been the basis for new medical device companies. 
Dr. David R. Fischell is a serial entrepreneur who has founded nine biomedical device companies in the last fifteen years. He is chairman of the Cornell University Biomedical Engineering Advisory Board, and a Fellow of the American Institute for Medical and Biological Engineering.